BMS/Pfizer deal accelerates Portola's anticoagulation antidote
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Pfizer have signed a clinical collaboration agreement with Portola to conduct a proof-of-concept study investigating Portola's universal Factor Xa inhibitor antidote, PRT4445, with a view to accelerating the development of the drug as a potential antidote to BMS/Pfizer's oral Factor Xa inhibitor, Eliquis (apixaban).